Table 3.
The 2023 Bethesda System for Reporting Thyroid Cytopathology (This table is established using The 2023 Bethesda System for Reporting Thyroid Cytopathology guideline (67))
| Adult | Pediatric | |||||
|---|---|---|---|---|---|---|
| Diagnostic Category | ROM %Mean (min-max) |
Usual Management | ROM %Mean (min-max) |
Usual Management | ||
| Nondiagnostic | Bethesda I | %13 (5-20) | Repeat FNA with ultrasound guidance | %14 (0-33) | Repeat FNA with ultrasound guidance | |
| Benign | Bethesda II | %4 (2-7) | Clinical and ultrasound follow-up | %6 (0-27) | Clinical and ultrasound follow-up | |
| Atypia of undetermined significance | Bethesda III | %22 (13-30) | Repeat FNA, molecular testing, lobectomy, surveillance | %28 (11-54) | Repeat FNA, lobectomy | |
| Follicular Neoplasm | Bethesda IV | %30 (23-34) | Molecular testing, diagnostic lobectomy | %50 (%58-100) | Surgical resection | |
| Suspicious for malignancy | Bethesda V | %74 (67-83) | Molecular testing, lobectomy or near-total thyroidectomy | %81 (40-100) | Surgical resection | |
| Malignant | Bethesda VI | %97 (97-100) | Lobectomy or near-total thyroidectomy | %98 (86-100) | Surgical resection | |